Advanced Colorectal cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Colon cancer that develops locally, returns, spreads, or transforms into colon cancer that is challenging to surgically remove is referred to as advanced colorectal cancer. Approximately 50% of colorectal cancer patients die from subsequent metastases, despite the fact that the majority of patients can be successfully treated with curative surgery and adjuvant chemotherapy. For advanced colorectal cancer, the 5-year survival rate is less than 5%. Although colon and rectal cancer incidence varies greatly by nation, it is predicted that there will be 1,931,590 new cases globally in 2020. For advanced colorectal cancer (stages I through III), surgery is the only available treatment. The appropriateness of selective colectomy in patients with intact stage IV disease is still up for debate, even though surgical resection may be the only option for patients whose metastatic disease has spread only to the liver and/or lungs (stage IV disease). For patients with stage III disease, adjuvant chemotherapy is standard.

Description

Colon cancer that develops locally, returns, spreads, or transforms into colon cancer that is challenging to remove surgically is referred to as advanced colorectal cancer. Approximately 50% of colorectal cancer patients die from subsequent metastases, despite the fact that the majority of patients can be successfully treated with curative surgery and adjuvant chemotherapy. Advanced colorectal cancer has a less than 5% of 5-year survival rate. In the rectum as opposed to the primary colon, local tumor recurrence is more frequent. Early asymptomatic diagnosis is possible through observation or by looking for symptoms that are similar to those of the primary lesion. Rectal bleeding, mucus production, changes in bowel habits, and straining are typical symptoms of rectal cancer recurrence. Pelvic relapse is marked by pain and symptoms of the urinary tract. The focal signs of recurrent intra-abdominal disease include recurrence elsewhere, liver capsule pain, jaundice, dyspnea, localized bone pain, or neurological symptoms. They can also include small or large bowel obstruction. Advanced colorectal cancer frequently exhibits systemic symptoms, such as weakness, nausea, anorexia, and weight loss. Malignant ascites is a possibility, and tumors are typically palpable when the abdomen or rectum are examined.

Advanced Colorectal cancer (Epidemiology)

In 2020, colorectal cancer accounted for 1,931,590 cases of all new cancer cases globally. The incidence varies up to six-fold geographically. The estimated rates are 40.6 for men and 24.5 for women per 100,000 people in southern Europe, and 6.6 for men and 4.4 for women in south-central Asia. About 935,173 people died from colorectal cancer worldwide in 2020, which accounted for 9.4% of all cancer-related deaths. Similar to incidence rates, mortality rates also vary significantly by region, with the highest rates estimated in central and eastern Europe (14.5 per 100,000 people) and the lowest in south-central Asia (3.2 per 100,000 people). According to an epidemiologic study from the European Union (EU), colorectal cancer would cause 79,400 deaths in women and 98,000 deaths in men in 2018, ranking second among all cancers. While the number of colorectal deaths overall in the EU has increased since 2012 as a result of the aging population, the age-standardized death rate has decreased since 2012 by 6.7% for men and 7.5% for women, falling to 15.8 and 9.2, respectively. Incidence and mortality from colon cancer have been steadily declining in the United States over the past few decades, with incidence decreasing on average by 2.4% annually and death rates decreasing on average by 2.2% annually from 2007 to 2019. However, colorectal cancers continue to be the third most common cancer and the third most common cause of cancer-related mortality in US men and women. Additionally, the incidence of colon cancer in younger people has been rising.

Advanced Colorectal cancer -Current Market Size & Forecast Trends

The market for advanced colorectal cancer is projected to grow significantly, with estimates indicating a value of approximately USD 11.9 billion in 2023 and expected to reach around USD 17.99 billion by 2032, reflecting a compound annual growth rate (CAGR) of 4.7% during this period. The increasing prevalence of colorectal cancer, particularly colorectal adenocarcinoma, along with advancements in treatment options such as targeted therapies and immunotherapies, are key factors driving this growth. North America is anticipated to dominate the market due to its robust healthcare infrastructure and significant investment in research and development. Overall, the advanced colorectal cancer market is well-positioned for substantial growth through 2035 as new therapies and improved diagnostic technologies continue to emerge.

For advanced colorectal cancer (stages I through III), surgery is the only available treatment. The appropriateness of selective colectomy in patients with intact stage IV disease is still up for debate, even though surgical resection may be the only option for patients whose metastatic disease has spread only to the liver and/or lungs (stage IV disease). The standard treatment for patients with stage III disease is adjuvant chemotherapy. Current guidelines advise its use in some patients with relapse risk factors, despite the controversy surrounding its use in stage II disease. For some metastases, such as bone or brain metastases, radiotherapy is currently only used as palliative care. Patients with metastatic colorectal cancer are now typically treated with chemotherapy rather than surgery. The use of biologics in the treatment of metastatic disease has been significant, and tumor genetic analyses are becoming more and more important in the selection process. Debatable whether elective colon/rectectomy is necessary for patients with unobstructed stage IV disease. A combination of aggressive therapies, symptom management techniques, and psychosocial support are used in the treatment of advanced colorectal cancer. An individual treatment plan, frequently combining radiation therapy, cytotoxic chemotherapy, and palliative surgery, is considered active treatment. Obstructive lesions and pelvic symptoms are frequently treated with palliative surgical procedures for advanced colorectal cancer. The liver is the most frequent site of metastasis, and surgical resection is the only treatment option for some patients who do not have extrahepatic metastases. For this extremely specialized procedure, the 5-year survival rate is between 25% and 35%. Rarely is radiation therapy required for advanced colorectal cancer. Local radiation allows for the resection of some tumors in locally advanced rectal disease. Additionally, symptoms like pain relief, bleeding control, and tension reduction may benefit from radiation therapy. Radiotherapy can permanently control the tumor if there are no distant metastases. Short-term radiation therapy can also lessen the pain associated with isolated bone metastases. Chemotherapy is administered to colon cancer patients as a palliative measure rather than as a curative measure. The primary method of treatment for colon cancer for more than 40 years has been fluorouracil. Fluorouracil is administered intravenously before folinic acid to increase its cytotoxicity. Fluorouracil-based chemotherapy extended patients with advanced colorectal cancer's remaining survival time by roughly 4 to 6 months in a significant, randomized trial comparing chemotherapy to best supportive care. Around 40% of patients experience improved symptoms, weight gain, and functional performance after receiving chemotherapy, which also delays the onset or progression of symptoms by about six months. Palliative chemotherapy should not be administered to patients with advanced colorectal cancer unless they are physically fit and able to participate in activities.

Report Highlights

Advanced Colorectal cancer - Current Market Trends

Advanced Colorectal cancer - Current & Forecasted Cases across the G8 Countries

Advanced Colorectal cancer - Market Opportunities and Sales Potential for Agents

Advanced Colorectal cancer - Patient-based Market Forecast to 2035

Advanced Colorectal cancer - Untapped Business Opportunities

Advanced Colorectal cancer - Product Positioning Vis-a-vis Competitors' Products

Advanced Colorectal cancer - KOLs Insight